Validation of a comorbidity questionnaire in patients with neurological disorders.
clinical neurology
Journal
BMJ neurology open
ISSN: 2632-6140
Titre abrégé: BMJ Neurol Open
Pays: England
ID NLM: 101775450
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
05
2023
accepted:
13
08
2023
medline:
4
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Several tools exist to assess comorbidities in neurological disorders, the most widely used being the Charlson Comorbidity Index (CCI), but it has several limitations. The Comorbidity and General Health Questionnaire (CGHQ) is a newly designed tool, which includes additional comorbidities associated with health-related quality of life (HR-QOL) and outcomes in neurological disorders. To assess the feasibility and validity of the CGHQ in patients with neurological disease. Two hundred patients attending a general neurological clinic were invited to complete the CGHQ along with the EQ-5D-5L questionnaire. The CCI was simultaneously completed by the assessor. CGHQ comorbidity scores were compared with CCI, symptom burden and EQ-5D-5L scores. The CGHQ captured 22 additional comorbidities not included on the CCI and more comorbidities were endorsed on the CGHQ. The CGHQ correlated weakly to moderately with CCI comorbidity scores. While both the CGHQ and CCI correlated negatively with the EQ-5D-5L Visual Analogue Scale, only the CGHQ correlated negatively with the EQ-5D-5L summary index. The CGHQ but not the CCI correlated strongly and positively with symptom burden scores. The CGHQ allows a more comprehensive assessment of comorbidities than the CCI and better correlates with patients' overall symptom burden and HR-QOL in neurological patients.
Identifiants
pubmed: 37663868
doi: 10.1136/bmjno-2023-000464
pii: bmjno-2023-000464
pmc: PMC10471876
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e000464Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Qual Life Res. 2006 Feb;15(1):83-91
pubmed: 16411033
Eur Arch Psychiatry Clin Neurosci. 2013 Nov;263 Suppl 2:S123-36
pubmed: 24077889
Lancet. 2012 Jul 7;380(9836):37-43
pubmed: 22579043
Qual Life Res. 2016 Oct;25(10):2579-2592
pubmed: 27048497
Health Econ. 2018 Jan;27(1):7-22
pubmed: 28833869
Neurotherapeutics. 2017 Jan;14(1):161-175
pubmed: 27796917
Mult Scler Relat Disord. 2020 Jun;41:102010
pubmed: 32088654
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Aging Clin Exp Res. 2007 Dec;19(6):492-6
pubmed: 18172372
Epilepsy Behav. 2014 Dec;41:283-9
pubmed: 24998313
J R Coll Physicians Edinb. 2017 Mar;47(1):35-39
pubmed: 28569280
Med Sci Monit. 2019 Jun 18;25:4521-4526
pubmed: 31209196
Dement Geriatr Cogn Disord. 2019;48(1-2):93-104
pubmed: 31600747
BMC Geriatr. 2020 Mar 29;20(1):114
pubmed: 32223742
J Comorb. 2018 Sep 03;8(1):2235042X18795306
pubmed: 30363320
Med Care. 2015 Sep;53(9):e65-72
pubmed: 23703645
CMAJ Open. 2017 Sep 25;5(3):E729-E733
pubmed: 28947426
Neuropsychopharmacology. 2020 Jan;45(1):129-140
pubmed: 31302665
J Neurol Neurosurg Psychiatry. 2000 Feb;68(2):202-6
pubmed: 10644788
J Thromb Haemost. 2018 Feb;16(2):242-252
pubmed: 29171148
Parkinsonism Relat Disord. 2016 Jul;28:124-9
pubmed: 27210815
Epilepsia. 2015 May;56(5):e68-72
pubmed: 25845308
Lancet Neurol. 2015 Dec;14(12):1206-18
pubmed: 26581971
Front Public Health. 2018 Jun 11;6:149
pubmed: 29942800